All In Biotech

Drug Trial Radar · NCT01189097

Combined Therapy of Methadone and Dextromethrophan

Combined Therapy of Methadone and Dextromethrophan: A Novel Strategy for the Treatment of Opioid Dependence

Last checked: Nov 19, 2026Latest source record: Aug 26, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,500

Planned (sponsor's estimate)

Start

Apr 2008

Primary completion

Mar 2011

Study completion Sep 2011

Sponsor

Lead sponsor
National Cheng-Kung University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the pharmacological effects and outcomes of DM therapy with this add-on study. And to determine the immunological changes between the baseline and the end point of the study.

Conditions

  • Opioid Abuse

Interventions

  • DextromethorphanDrug

    Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.

  • DextromethorphanDrug

    Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urinary examinationTime frame: baseline
  2. Urinary examinationTime frame: week 1
  3. Urinary examinationTime frame: week2
  4. Urinary examinationTime frame: week4
  5. Urinary examinationTime frame: week8
  6. Urinary examinationTime frame: week12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ru-Band Lu

    Tainan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.